HU-243

HU-243

Identifiers
IUPAC name (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol
CAS Number	140835-18-3 Y
PubChem CID	3081854
IUPHAR/BPS	735
Chemical and physical data
Formula	C25H40O3
Molar mass	388.30 g/mol
3D model (Jmol)	Interactive image
SMILES CC(O1)(C)[C@H]2[C@@H](C[C@H](CO)CC2)C3=C1C=C(C(C)(C)CCCCCC)C=C3O

HU-243 (AM-4056) is a synthetic cannabinoid drug that is a single enantiomer of the hydrogenated derivative of the commonly used reference agonist HU-210. It is a methylene homologue of canbisol. It is a potent agonist at both the CB₁ and CB₂ receptors, with a binding affinity of 0.041 nM at the CB₁ receptor, making it marginally more potent than HU-210, which had an affinity of 0.061 nM in the same assay.

HU-243 is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971, so the signatory countries to these international drug control treaties are not required by said treaties to control HU-243.

HU-243 is not listed in the list of scheduled controlled substances in the USA. It is therefore not scheduled at the federal level in the United States, but it is possible that HU-243 could legally be considered an analog of THC (which is one of the substances controlled in Schedule I as "tetrahydrocannabinols") or another synthetic Schedule I cannabinoids such as CP-47,497, and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.